Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | STK25 | O00506 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13487580 | 0.84 | AGTR1 (0.50) | RAB9AAGTR1KDM4EMAPK14HPGD | |
| SCHEMBL13487583 | 0.73 | MAPK14 (0.49) | MAPK14ALDH1A1SMN1; SMN2MAPTSTK25 | |
| SCHEMBL13315133 | 0.70 | ALDH1A1 (0.43) | RAB9AHPGDALDH1A1SMN1; SMN2STK25 | |
| SCHEMBL13315134 | 0.69 | MEN1 (0.42) | KDM4EMAPK14HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL13315141 | 0.65 | MAPT (0.43) | KDM4EALDH1A1SMN1; SMN2GAAMAPT | |
| SCHEMBL1263133 | 0.63 | HPGD (0.88) | HPGDALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL2614241 | 0.61 | HPGD (0.84) | HPGDALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL5320792 | 0.61 | RAB9A (0.65) | RAB9AAGTR1KDM4EHPGDALDH1A1 | |
| SCHEMBL4409746 | 0.61 | HPGD (0.66) | HPGDALDH1A1SMN1; SMN2GAAKMT2A | |
| SCHEMBL254870 | 0.60 | HPGD (0.96) | HPGDALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | MAP4K2, MAP3K1, MAP3K20 | RAB9A 2804/4885AGTR1 2911/4885KDM4E 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.